This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Carol L. Shields, MD; Santosh G. Honavar, MD; Anna T. Meadows, MD; Jerry A. Shields, MD; Hakan Demirci, MD; Thomas John Naduvilath, MSc

Arch Ophthalmol. 2002;120:1653-1658.

Objective  To evaluate conservative management of unilateral retinoblastoma using chemoreduction and focal treatment.

Design  Prospective nonrandomized single-center clinical trial.

Setting  Ocular Oncology Service at Wills Eye Hospital of Thomas Jefferson University, Philadelphia, Pa, in conjunction with the Division of Oncology at The Children's Hospital of Philadelphia.

Participants  Thirty eyes of 30 patients with unilateral retinoblastoma treated with chemoreduction between June 1, 1994, and August 31, 1999, that would otherwise have been managed with enucleation or external beam radiotherapy.

Intervention  All patients received treatment for retinoblastoma with a planned 6 cycles of chemoreduction using vincristine sulfate, etoposide, and carboplatin, combined with focal treatment (cryotherapy or thermotherapy) to each retinal tumor.

Main Outcome Measures  The main outcome measure was the postchemoreduction need for external beam radiotherapy or enucleation. The cumulative probability of each outcome was estimated using Kaplan-Meier survival analysis. A secondary outcome measure was final visual acuity in the affected eye. The clinical features at the time of patient presentation were analyzed for their impact on the main outcomes using a series of Fisher exact tests and Cox proportional hazards regressions.

Results  Eighteen eyes (60%) were classified as having Reese-Ellsworth (RE) groups I through IV retinoblastoma and 12 eyes (40%), group V retinoblastoma. By using Kaplan-Meier estimates, we found a need for either external beam radiotherapy or enucleation in 68% of eyes by 5 years. In fact, 38% of those in groups I through IV required either treatment, whereas all of those in group V required the additional use of either treatment. Specifically, the need for external beam radiotherapy occurred in 27% of eyes by 5 years. Eleven percent of those in groups I through IV and 50% of group V required external beam radiotherapy by 5 years. The factors predictive of the need for external beam radiotherapy included RE group V disease, tumor thickness greater than 5 mm, and presence of vitreous seeds. The need for enucleation occurred in 47% of eyes by 5 years using Kaplan-Meier analysis. Specifically, 29% of those in groups I through IV and 67% of group V required enucleation by 5 years. The factors predictive of the need for enucleation included age at diagnosis older than 12 months, RE group V disease, tumor base diameter greater than 15 mm, and tumor thickness greater than 5 mm.

At a mean follow-up of 29 months, the final visual acuity was 20/200 or better in 6 eyes (20%) and worse than 20/200 in 14 (47%); enucleation was needed in 10 (33%). Of the 26 eyes with initial macular involvement of retinoblastoma, final visual acuity was 20/200 or better in 6 (23%). No patient developed retinoblastoma metastasis, pinealoblastoma, or second malignant neoplasms.

Conclusions  Chemoreduction is an option for selected eyes with unilateral retinoblastoma. Those with advanced RE group V retinoblastoma showed poorest results, while those with less advanced groups I through IV disease showed best results, maintaining the globe in 71% of eyes, sometimes with satisfactory functional visual acuity.

From the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University (Drs C. L. Shields, Honavar, J. A. Shields, and Demirci), and the Division of Oncology, The Children's Hospital of Philadelphia (Dr Meadows), Philadelphia, Pa; and the Ocular Oncology Service, LV Prasad Eye Institute, Hyderabad, India (Dr Honavar and Mr Naduvilath).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Emerging options in the management of advanced intraocular retinoblastoma
Honavar
Br J Ophthalmol 2009;93:848-849.
FULL TEXT  

The success of primary chemotherapy for group D heritable retinoblastoma
Cohen et al.
Br J Ophthalmol 2009;93:887-890.
ABSTRACT | FULL TEXT  

Clinical manifestations and treatment of retinoblastoma in Korea
Chung et al.
Br J Ophthalmol 2008;92:1180-1184.
ABSTRACT | FULL TEXT  

The Adverse Events of Chemotherapy for Retinoblastoma: What Are They? Do We Know?
Rizzuti et al.
Arch Ophthalmol 2008;126:862-865.
FULL TEXT  

Socioeconomic Impact of Modern Multidisciplinary Management of Retinoblastoma
Wilson et al.
Pediatrics 2006;118:e331-e336.
ABSTRACT | FULL TEXT  

Case 5-2006 -- An 11-Year-Old Girl with Loss of Vision in the Right Eye
Walton et al.
NEJM 2006;354:741-748.
FULL TEXT  

Chemoreduction With Topical Mitomycin C Prior to Resection of Extensive Squamous Cell Carcinoma of the Conjunctiva
Shields et al.
Arch Ophthalmol 2005;123:109-113.
FULL TEXT  

Outcome Following Initial External Beam Radiotherapy in Patients With Reese-Ellsworth Group Vb Retinoblastoma
Abramson et al.
Arch Ophthalmol 2004;122:1316-1323.
ABSTRACT | FULL TEXT